GENE ONLINE|News &
Opinion
Blog

2023-04-17| Partnerships

Pyramid Biosciences Bets $1B on Oncology Drug

by Nai Ye Yeat
Share To

The privately-held US biotech Pyramid Biosciences has entered into an exclusive license agreement with China’s GeneQuantum Healthcare to develop and commercialize GQ1010, a potential best-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2).  

Under the terms of the agreement, Pyramid gains exclusive rights to develop and commercialize GQ-1010 globally, excluding greater China (mainland China, Hong Kong, Macau, and Taiwan). In exchange, GeneQuantum will receive an up-front payment of $20 million and up to an additional $1 billion in milestone payments. 

Related article: Pfizer Acquires Seagen for $43 Billion to Capture Leading Position in Oncology 

ADCs, the Next Era of Targeted Therapy

ADCs are a class of drugs designed as a targeted therapy to treat various diseases, but their application is only limited to cancer currently. They are complex molecules consisting of an antibody linked to a biologically active cytotoxic payload or drug. 

Unlike traditional chemotherapy which is often associated with poor therapeutic response and substantial toxicities to normal healthy tissues, antibody-drug conjugates target and kill tumor cells without harming the healthy cells, by integrating the antigen specificity of monoclonal antibodies (mAbs) with antibody fragments. 

To date, more than 10 ADCs have been approved by the FDA, and around a hundred of its kind are under worldwide clinical development.

Key to Expand Oncology Drug Portfolio

GQ1010 utilizes a unique site-specific conjugation technology and incorporates a novel linker payload which may lead to improved stability, safety, and potency of the ADC. Its target, TROP2, is a cell surface glycoprotein highly expressed in a variety of neoplasms, including breast, lung, pancreatic, ovarian, and prostate cancer, and plays a key role in tumor cell proliferation.

GQ1010 is scheduled to enter a first-in-human trial within the next 12 months, providing that the preclinical data has reported a broader therapeutic margin of the drug compared to more advanced TROP2 ADCs.  

If ultimately approved, the drug would rival Gilead’s first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy, that the drugmaker picked up in its $21 billion buyout of Immunomedics in 2020. Trodelvy is currently approved for certain breast cancer treatments as well as advanced urothelial cancer.

Despite the fierce competition in the ADCs market, both companies are optimistic that their partnership will rapidly advance the worldwide development of GQ1010, and help patients overcome their cancer with the success of delivering transformative medicines to those in need.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The Fight Against Hard-to-Treat Cancers : Bold Bets on a Multifaceted Approach
2025-05-19
May
AI-Based Model Accurately Classifies Pediatric Sarcomas Using Digital Pathology Images
2025-04-30
Layoffs in Biotech and Pharma: A March 2025 Snapshot by Therapeutic and Technology Focus
2025-04-03
LATEST
University of Pittsburgh Study Finds Flu Vaccines Prevent Up to 41.5 Percent of Infections in Simulated Communities
2025-07-19
Pharmacist-Led Initiatives Boost Pneumococcal Vaccine Uptake Among Older Adults Through Education and Direct Immunization Services
2025-07-19
Study Finds Agricultural Dust Exposure Alters Gut Microbiota and Weakens Intestinal Barrier in Mice
2025-07-19
Biotech Leaders Urge FDA to Reject Conservative Report Criticizing Mifepristone Safety Profile
2025-07-19
Physician Calls for Better Diagnosis of Cannabinoid Hyperemesis Syndrome Amid Discussions on Drug Pricing and Accessibility
2025-07-19
Maternal Vaccination Linked to Reduced RSV Hospitalizations in Newborns
2025-07-18
FDA Advisory Committee Votes Against Approval of GSK’s Blenrep Ahead of PDUFA Date
2025-07-18
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top